

internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

#### **Example 6**

##### **Oligonucleotide Isolation**

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by <sup>31</sup>P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, *266*, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

#### **Example 7**

##### **Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from

-70-

commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

#### **Example 8**

##### **Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

#### **Example 9**

##### **Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 5 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis,

-71-

Ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum ((Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

-72-

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

MCF7:

The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection (Manassas, VA). MCF-7 cells were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds:

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130  $\mu$ L of OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control

-73-

oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control

5 oligonucleotide is ISIS 15770, **ATGCATTCTGCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-ras. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for  
10 ISIS 13920) or c-ras (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-ras  
15 mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

#### 20 **Example 10**

#### **Analysis of oligonucleotide inhibition of mucin 1, transmembrane expression**

Antisense modulation of mucin 1, transmembrane expression  
25 can be assayed in a variety of ways known in the art. For example, mucin 1, transmembrane mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be  
30 performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1,  
35 pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons,

-74-

Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of mucin 1, transmembrane can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to mucin 1, transmembrane can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

#### **Example 11**

##### **Poly(A)+ mRNA isolation**

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-

-75-

4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

## Example 12

### Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 150  $\mu$ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150  $\mu$ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500  $\mu$ L of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. An additional 500  $\mu$ L of Buffer RW1

-76-

was added to each well of the RNEASY 96™ plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 µL water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

### **Example 13**

#### **Real-time Quantitative PCR Analysis of mucin 1, transmembrane mRNA Levels**

Quantitation of mucin 1, transmembrane mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM, obtained from either Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g.,



-77-

TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen, Carlsbad, CA. RT-PCR reactions were carried out by adding 20 µL PCR cocktail

-78-

(2.5x PCR buffer (-MgCl<sub>2</sub>), 6.6 mM MgCl<sub>2</sub>, 375 μM each of dATP, dCTP, dGTP and dTTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96 well plates containing 30 μL total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, Analytical Biochemistry, 1998, 265, 368-374.

In this assay, 170 μL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human mucin 1, transmembrane were designed to hybridize to a human mucin 1, transmembrane sequence, using published sequence information (GenBank accession number NM\_002456.1, incorporated herein as SEQ ID NO:3). For human mucin 1, transmembrane the PCR primers were: forward primer: TGACTCTGGCCTTCCGAGAA (SEQ ID NO: 4) reverse primer: GCTGCTTCCGTTTATACTGATTG (SEQ ID NO: 5) and the PCR probe was: FAM-TACCATCAATGTCCACGACGTGGAGACA-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human

-79-

GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:7)

reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO:8) and the PCR probe was: 5' JOE-CAAGCTTCCCGTCTCAGCC-TAMRA 3' (SEQ ID NO: 9)

5 where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

#### 10 **Example 14**

##### **Northern blot analysis of mucin 1, transmembrane mRNA levels**

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAzol™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared  
15 following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham  
20 Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La  
25 Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

To detect human mucin 1, transmembrane, a human mucin 1, transmembrane specific probe was prepared by PCR using the  
30 forward primer TGACTCTGGCCTTCCGAGAA (SEQ ID NO: 4) and the reverse primer GCTGCTTCCGTTTATACTGATTG (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

35 Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels

in untreated controls.

#### Example 15

#### 5 Antisense inhibition of human mucin 1, transmembrane expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human mucin 1, transmembrane RNA, using published sequences (GenBank accession number NM\_002456.1, representing the main mRNA of mucin 1, transmembrane, incorporated herein as SEQ ID NO: 3; GenBank accession number AF125525.1, representing the variant MUC1/Y, incorporated herein as SEQ ID NO: 10; GenBank  
10 accession number AF348143.1, representing a variant of mucin 1, transmembrane herein designated MUC1-II, incorporated herein as SEQ ID NO: 11; GenBank accession number AI834269.1, representing a variant of mucin 1, transmembrane herein designated MUC1-III, the complement of which is incorporated herein as SEQ ID NO: 12;  
15 GenBank accession number AW369441.1, representing a variant of mucin 1, transmembrane herein designated MUC1-IV, incorporated herein as SEQ ID NO: 14; GenBank accession number BG774910.1, representing a variant of mucin 1, transmembrane herein designated MUC1-V, incorporated herein as SEQ ID NO: 16; GenBank  
20 accession number J05581.1, representing a variant of mucin 1, transmembrane herein designated MUC1-VI, incorporated herein as SEQ ID NO: 17; GenBank accession number M31823.1, representing a variant of mucin 1, transmembrane herein designated MUC1-VII, incorporated herein as SEQ ID NO: 18; GenBank accession number  
25 M61170, representing a genomic sequence of mucin 1, transmembrane, incorporated herein as SEQ ID NO: 19; GenBank accession number U60259.1, representing the variant MUC1/X, incorporated herein as SEQ ID NO: 20; and GenBank accession number Z17325.1, representing the variant MUC1/D, incorporated  
30 herein as SEQ ID NO: 21). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric

-81-

oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human mucin 1, transmembrane mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human mucin 1, transmembrane mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
199396	5'UTR	3	8	gaacagattcaagcagccag	0	22
199397	Start Codon	3	49	cccggtgtcatggtggtggt	58	23
199398	Start Codon	3	52	gtgcccggtgtcatggtggt	58	24
199399	Coding	3	65	gaaaggagactgggtgcccg	54	25
199400	Coding	3	105	ctgtaacaactgtaagcact	41	26
199401	Coding	3	107	acctgtaacaactgtaagca	53	27
199402	Coding	3	187	tcagtagagctgggactga	55	28
199403	Coding	3	196	gcattcttctcagtagagct	77	29
199404	Coding	3	197	agcattcttctcagtagagc	50	30
199405	Coding	3	210	tggtcatactcacagcattc	42	31
199406	Coding	3	214	ctgctgggtcactactcacagc	56	32
199407	Coding	3	227	gctggagagtacgctgctgg	57	33
199408	Coding	3	344	tgggaccgaggtgacatcct	65	34
199409	Coding	3	694	gtgacattgtggactggagg	55	35
199410	Coding	3	697	gaggtgacattgtggactgg	57	36
199411	Coding	3	704	tgaggccgaggtgacattgt	54	37
199412	Coding	3	829	gtggtaggagatcacagagt	53	38
199413	Coding	3	835	gcaagggtggtaggagatc	50	39
199414	Coding	3	860	ggcatcagtccttggctctat	53	40
199415	Coding	3	940	gagacccagtagacaactg	24	41
199416	Coding	3	997	tcttccagagaggaataaa	41	42
199417	Coding	3	1037	aatgtctctctgcagctctt	41	43
199418	Coding	3	1042	tcagaaatgtctctctgcag	54	44
199419	Coding	3	1056	tctgcaaaaacatttcagaa	45	45

199420	Coding	3	1065	gtttataaatctgcaaaaac	39	46
199421	Coding	3	1091	attggagagggcccagaaaac	41	47
199422	Coding	3	1095	taatattggagagggcccaga	50	48
199423	Coding	3	1100	gaacttaaatattggagagggc	48	49
199424	Coding	3	1112	agatcctggcctgaacttaa	53	50
199425	Coding	3	1115	cacagatcctggcctgaact	49	51
199426	Coding	3	1168	acgtcgtggacattgatgggt	84	52
199427	Coding	3	1217	gttatatcgagaggctgctt	50	53
199428	Coding	3	1225	atcgtaaggttatatcgaga	47	54
199429	Coding	3	1251	gcacatcactcacgctgacg	50	55
199430	Coding	3	1268	ggcagagaaaggaaaatggca	46	56
199431	Coding	3	1371	gacagacagccaaggcaatg	47	57
199432	Coding	3	1397	ctgcccgtagttcttctgcgc	43	58
199433	Coding	3	1412	tggaaagatgtccagctgcc	41	59
199434	Coding	3	1499	gctacgatcgggtactgctag	52	60
199435	Coding	3	1540	aggctgctgccaccattacc	59	61
199436	Coding	3	1582	aagttggcagaagtggctgc	42	62
199437	Stop Codon	3	1586	ctacaagttggcagaagtgg	35	63
199438	Stop Codon	3	1594	acgtgcccctacaagttggc	57	64
199439	3'UTR	3	1606	gctcagagggcgagctgccc	36	65
199440	3'UTR	3	1617	ctggccactcagctcagagg	56	66
199441	3'UTR	3	1622	actggctggccactcagctc	55	67
199442	3'UTR	3	1630	ggaatggcactggctggcca	60	68
199443	3'UTR	3	1635	ggagtggatggcactggct	56	69
199444	Coding	10	141	aggaattaaaagcattcttc	7	70
199445	Coding	11	174	cagtagacaaagcattcttc	40	71
199446	Coding	11	297	gacagacagccatttcagaa	80	72
199447	Exon: Exon Junction	12	49	catcactcactgaacttaat	1	73
199448	Intron 6	19	5327	tttgggtttttccaagtaccc	83	74
199449	Intron 6	19	5436	catagtctcctcccaggcct	44	75
199450	Intron 6	19	5588	catttttgctctgggtgcaa	49	76
199451	Exon: Exon Junction	14	160	cagccccagacatttcagaa	21	77
199452	Intron 1	19	3289	ttctctctgcccattaggcct	42	78
199453	Intron 1	19	3426	gggtctttatgaaggaaaaa	43	79
199454	Exon: Exon Junction	16	455	acatcactcactcatttcagaa	62	80
199455	3'UTR	17	1776	accacgtttttattcagtcga	65	81
199456	Coding	18	115	gctgtggtagctgtaagcac	38	82
199457	Coding	20	175	gtgctgggatagcattcttc	15	83
199458	Coding	20	245	agagtcattgtaccaccac	2	84
199459	Coding	21	122	ttttctccacctgtaagcac	18	85
199460	Intron: Exon Junction	19	3489	cctgtaacaactgttgcgagg	32	86
199461	Intron: Exon	19	3498	tgaccagaacctgtaacaac	38	87

-83-

	Junction					
199462	Exon 2d	19	3530	tctcctttttctccacctggg	49	88
199463	Exon 2d	19	3571	ctcagtagagctgggcaactg	47	89
199464	Exon 2d	19	3590	tcatactcacagcattcttc	42	90
199465	Exon: Intron Junction	19	3973	agagcctgaggccgaggtga	58	91
199466	Intron: Exon Junction	19	4201	gaccccgtagacaactggg	20	92
199467	Intron: Exon Junction	19	4250	aggaattaaactggaggttt	55	93
199468	Exon 3d	19	4269	gtgctgggatcttccagaga	61	94
199469	Intron: Exon Junction	19	4621	atcctggcctgggtcacaggg	39	95
199470	Exon 5	19	4936	cagcccccagactgggcagag	41	96
199471	Intron 6	19	5449	ggccctttcttccatagtc	55	97
199472	Intron 6	19	5889	ccacctggagtggttttcca	42	98
199473	Intron 6	19	5956	aaagccgagagagggaggtc	51	99

As shown in Table 1, SEQ ID NOS 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 66, 67, 68, 69, 72, 74, 75, 76, 78, 79, 80, 81, 88, 89, 90, 91, 93, 94, 96, 97, 98 and 99 demonstrated at least 41% inhibition of human mucin 1, transmembrane expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

#### Example 16

##### Western blot analysis of mucin 1, transmembrane protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to mucin 1, transmembrane is used,

-84-

with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

5

**Example 17****Targeting of individual oligonucleotides to specific variants of mucin 1, transmembrane**

It is advantageous to selectively inhibit the expression of one or more variants of mucin 1, transmembrane. Consequently, in one embodiment of the present invention are oligonucleotides that selectively target, hybridize to, and specifically inhibit one or more, but fewer than all of the variants of mucin 1, transmembrane. A summary of the target sites of the variants is shown in Table 2 and includes Genbank accession number NM\_002456.1, representing mucin 1, transmembrane (MUC1), incorporated herein as SEQ ID NO: 3; Genbank accession number AF125525.1, representing MUC1/Y, incorporated herein as SEQ ID NO: 10; Genbank accession number AF348143.1, representing MUC1-II, incorporated herein as SEQ ID NO: 11; Genbank accession number AI834269.1, representing MUC1-III, incorporated herein as SEQ ID NO: 12; Genbank accession number AW369441.1, representing MUC1-IV, incorporated herein as SEQ ID NO: 14; Genbank accession number BG774910.1, representing MUC1-V, incorporated herein as SEQ ID NO: 16; Genbank accession number J05581.1, representing MUC1-VI, incorporated herein as SEQ ID NO: 17; Genbank accession number M31823.1, representing MUC1-VII, incorporated herein as SEQ ID NO: 18; Genbank accession number U60259.1, representing MUC1/X, incorporated herein as SEQ ID NO: 20; Genbank accession number Z17325.1, representing MUC1/D, incorporated herein as SEQ ID NO: 21; Genbank accession number S81781.1, representing the variant MUC1/A, incorporated herein as SEQ ID NO: 100; Genbank accession number M32738.1, representing the variant MUC1/REP, incorporated herein as SEQ ID NO: 101; Genbank accession number M35093.1, representing the variant MUC1/SEC, incorporated herein as SEQ ID NO: 102; Genbank accession number U60261.1, representing the variant MUC1/Z, incorporated herein as SEQ ID NO: 103; Genbank accession number Z17324.1, representing the



-85-

variant MUC1/C, incorporated herein as SEQ ID NO: 104; Genbank accession number BF876382.1, representing a variant of mucin 1, transmembrane herein designated MUC1-VIII, incorporated herein as SEQ ID NO: 105; Genbank accession number BG541121.1, representing a variant of mucin 1, transmembrane herein designated MUC1-IX, incorporated herein as SEQ ID NO: 106; Genbank accession number AL046435.1, representing a variant of mucin 1, transmembrane herein designated MUC1-X, incorporated herein as SEQ ID NO: 107.

10

Table 2

Targeting of individual oligonucleotides to specific variants of mucin 1, transmembrane

ISIS #	OLIGO SEQ ID NO.	TARGET SITE	VARIANT	VARIANT SEQ ID NO.
199396	22	8	MUC1	3
199397	23	49	MUC1	3
199397	23	16	MUC1-II	11
199397	23	64	MUC1-VI	17
199397	23	58	MUC1-VII	18
199397	23	17	MUC1/X	20
199397	23	65	MUC1/D	21
199397	23	1	MUC1/A	100
199397	23	42	MUC1/REP	101
199397	23	776	MUC1/SEC	102
199397	23	17	MUC1/Z	103
199397	23	65	MUC1/C	104
199397	23	59	MUC1-IX	106
199398	24	52	MUC1	3
199398	24	19	MUC1-II	11
199398	24	67	MUC1-VI	17
199398	24	61	MUC1-VII	18
199398	24	20	MUC1/X	20
199398	24	68	MUC1/D	21
199398	24	4	MUC1/A	100
199398	24	45	MUC1/REP	101
199398	24	779	MUC1/SEC	102
199398	24	20	MUC1/Z	103
199398	24	68	MUC1/C	104
199398	24	62	MUC1-IX	106
199399	25	65	MUC1	3
199399	25	8	MUC1/Y	10
199399	25	32	MUC1-II	11
199399	25	80	MUC1-VI	17
199399	25	74	MUC1-VII	18
199399	25	33	MUC1/X	20

199399	25	81	MUC1/D	21
199399	25	17	MUC1/A	100
199399	25	58	MUC1/REP	101
199399	25	792	MUC1/SEC	102
199399	25	33	MUC1/Z	103
199399	25	81	MUC1/C	104
199399	25	75	MUC1-IX	106
199400	26	105	MUC1	3
199400	26	72	MUC1-II	11
199400	26	120	MUC1-VI	17
199400	26	73	MUC1/X	20
199400	26	73	MUC1/Z	103
199401	27	107	MUC1	3
199401	27	74	MUC1-II	11
199401	27	122	MUC1-VI	17
199401	27	75	MUC1/X	20
199401	27	75	MUC1/Z	103
199402	28	187	MUC1	3
199402	28	121	MUC1/Y	10
199402	28	154	MUC1-II	11
199402	28	202	MUC1-VI	17
199402	28	223	MUC1-VII	18
199402	28	155	MUC1/X	20
199402	28	166	MUC1/A	100
199402	28	207	MUC1/REP	101
199402	28	1413	MUC1/SEC	102
199402	28	155	MUC1/Z	103
199402	28	346	MUC1-VIII	105
199402	28	224	MUC1-IX	106
199403	29	196	MUC1	3
199403	29	130	MUC1/Y	10
199403	29	163	MUC1-II	11
199403	29	211	MUC1-VI	17
199403	29	232	MUC1-VII	18
199403	29	164	MUC1/X	20
199403	29	175	MUC1/A	100
199403	29	216	MUC1/REP	101
199403	29	1422	MUC1/SEC	102
199403	29	164	MUC1/Z	103
199403	29	355	MUC1-VIII	105
199403	29	233	MUC1-IX	106
199404	30	197	MUC1	3
199404	30	131	MUC1/Y	10
199404	30	164	MUC1-II	11
199404	30	212	MUC1-VI	17
199404	30	233	MUC1-VII	18
199404	30	165	MUC1/X	20
199404	30	176	MUC1/A	100
199404	30	217	MUC1/REP	101
199404	30	1423	MUC1/SEC	102
199404	30	165	MUC1/Z	103
199404	30	356	MUC1-VIII	105
199404	30	234	MUC1-IX	106

199405	31	210	MUC1	3
199405	31	225	MUC1-VI	17
199405	31	246	MUC1-VII	18
199405	31	189	MUC1/A	100
199405	31	230	MUC1/REP	101
199405	31	1436	MUC1/SEC	102
199405	31	369	MUC1-VIII	105
199406	32	214	MUC1	3
199406	32	229	MUC1-VI	17
199406	32	250	MUC1-VII	18
199406	32	193	MUC1/A	100
199406	32	234	MUC1/REP	101
199406	32	1440	MUC1/SEC	102
199406	32	373	MUC1-VIII	105
199407	33	227	MUC1	3
199407	33	242	MUC1-VI	17
199407	33	263	MUC1-VII	18
199407	33	206	MUC1/A	100
199407	33	247	MUC1/REP	101
199407	33	1453	MUC1/SEC	102
199407	33	386	MUC1-VIII	105
199408	34	344	MUC1	3
199408	34	359	MUC1-VI	17
199408	34	380	MUC1-VII	18
199408	34	364	MUC1/REP	101
199408	34	1570	MUC1/SEC	102
199409	35	694	MUC1	3
199409	35	93	MUC1-V	16
199409	35	589	MUC1-VI	17
199409	35	1800	MUC1/SEC	102
199410	36	697	MUC1	3
199410	36	96	MUC1-V	16
199410	36	592	MUC1-VI	17
199410	36	1803	MUC1/SEC	102
199411	37	704	MUC1	3
199411	37	103	MUC1-V	16
199411	37	599	MUC1-VI	17
199411	37	1810	MUC1/SEC	102
199412	38	829	MUC1	3
199412	38	228	MUC1-V	16
199412	38	724	MUC1-VI	17
199412	38	1935	MUC1/SEC	102
199413	39	835	MUC1	3
199413	39	234	MUC1-V	16
199413	39	730	MUC1-VI	17
199413	39	1941	MUC1/SEC	102
199414	40	860	MUC1	3
199414	40	259	MUC1-V	16
199414	40	755	MUC1-VI	17
199414	40	1966	MUC1/SEC	102
199415	41	940	MUC1	3
199415	41	44	MUC1-IV	14
199415	41	339	MUC1-V	16

199415	41	835	MUC1-VI	17
199415	41	2046	MUC1/SEC	102
199416	42	997	MUC1	3
199416	42	151	MUC1/Y	10
199416	42	238	MUC1-II	11
199416	42	101	MUC1-IV	14
199416	42	396	MUC1-V	16
199416	42	892	MUC1-VI	17
199416	42	2103	MUC1/SEC	102
199416	42	239	MUC1/Z	103
199416	42	254	MUC1-IX	106
199417	43	1037	MUC1	3
199417	43	191	MUC1/Y	10
199417	43	278	MUC1-II	11
199417	43	141	MUC1-IV	14
199417	43	436	MUC1-V	16
199417	43	932	MUC1-VI	17
199417	43	206	MUC1/X	20
199417	43	2143	MUC1/SEC	102
199417	43	279	MUC1/Z	103
199417	43	294	MUC1-IX	106
199418	44	1042	MUC1	3
199418	44	196	MUC1/Y	10
199418	44	283	MUC1-II	11
199418	44	146	MUC1-IV	14
199418	44	441	MUC1-V	16
199418	44	937	MUC1-VI	17
199418	44	211	MUC1/X	20
199418	44	2148	MUC1/SEC	102
199418	44	284	MUC1/Z	103
199418	44	299	MUC1-IX	106
199419	45	1056	MUC1	3
199419	45	210	MUC1/Y	10
199419	45	951	MUC1-VI	17
199419	45	298	MUC1/Z	103
199419	45	313	MUC1-IX	106
199420	46	1065	MUC1	3
199420	46	219	MUC1/Y	10
199420	46	3	MUC1-III	12
199420	46	960	MUC1-VI	17
199420	46	2270	MUC1/SEC	102
199420	46	307	MUC1/Z	103
199420	46	322	MUC1-IX	106
199421	47	1091	MUC1	3
199421	47	245	MUC1/Y	10
199421	47	29	MUC1-III	12
199421	47	986	MUC1-VI	17
199421	47	2296	MUC1/SEC	102
199421	47	333	MUC1/Z	103
199421	47	348	MUC1-IX	106
199422	48	1095	MUC1	3
199422	48	249	MUC1/Y	10
199422	48	33	MUC1-III	12

199422	48	990	MUC1-VI	17
199422	48	2300	MUC1/SEC	102
199422	48	337	MUC1/Z	103
199422	48	352	MUC1-IX	106
199423	49	1100	MUC1	3
199423	49	254	MUC1/Y	10
199423	49	38	MUC1-III	12
199423	49	995	MUC1-VI	17
199423	49	2305	MUC1/SEC	102
199423	49	342	MUC1/Z	103
199423	49	357	MUC1-IX	106
199424	50	1112	MUC1	3
199424	50	266	MUC1/Y	10
199424	50	1007	MUC1-VI	17
199424	50	354	MUC1/Z	103
199424	50	369	MUC1-IX	106
199425	51	1115	MUC1	3
199425	51	269	MUC1/Y	10
199425	51	1010	MUC1-VI	17
199425	51	357	MUC1/Z	103
199425	51	372	MUC1-IX	106
199426	52	1168	MUC1	3
199426	52	1063	MUC1-VI	17
199426	52	281	MUC1/X	20
199426	52	2524	MUC1/SEC	102
199426	52	410	MUC1/Z	103
199426	52	425	MUC1-IX	106
199427	53	1217	MUC1	3
199427	53	371	MUC1/Y	10
199427	53	1112	MUC1-VI	17
199427	53	330	MUC1/X	20
199427	53	2573	MUC1/SEC	102
199427	53	459	MUC1/Z	103
199427	53	473	MUC1-IX	106
199428	54	1225	MUC1	3
199428	54	379	MUC1/Y	10
199428	54	1120	MUC1-VI	17
199428	54	338	MUC1/X	20
199428	54	2581	MUC1/SEC	102
199428	54	467	MUC1/Z	103
199428	54	481	MUC1-IX	106
199429	55	1251	MUC1	3
199429	55	405	MUC1/Y	10
199429	55	1146	MUC1-VI	17
199429	55	364	MUC1/X	20
199429	55	493	MUC1/Z	103
199429	55	507	MUC1-IX	106
199430	56	1268	MUC1	3
199430	56	422	MUC1/Y	10
199430	56	69	MUC1-III	12
199430	56	474	MUC1-V	16
199430	56	1163	MUC1-VI	17
199430	56	381	MUC1/X	20

199430	56	510	MUC1/Z	103
199431	57	1371	MUC1	3
199431	57	525	MUC1/Y	10
199431	57	250	MUC1-IV	14
199431	57	577	MUC1-V	16
199431	57	1266	MUC1-VI	17
199431	57	484	MUC1/X	20
199431	57	613	MUC1/Z	103
199431	57	76	MUC1-X	107
199432	58	1397	MUC1	3
199432	58	551	MUC1/Y	10
199432	58	276	MUC1-IV	14
199432	58	603	MUC1-V	16
199432	58	1292	MUC1-VI	17
199432	58	510	MUC1/X	20
199432	58	2977	MUC1/SEC	102
199432	58	639	MUC1/Z	103
199432	58	102	MUC1-X	107
199433	59	1412	MUC1	3
199433	59	566	MUC1/Y	10
199433	59	291	MUC1-IV	14
199433	59	618	MUC1-V	16
199433	59	1307	MUC1-VI	17
199433	59	525	MUC1/X	20
199433	59	2992	MUC1/SEC	102
199433	59	654	MUC1/Z	103
199433	59	117	MUC1-X	107
199434	60	1499	MUC1	3
199434	60	653	MUC1/Y	10
199434	60	425	MUC1-II	11
199434	60	378	MUC1-IV	14
199434	60	704	MUC1-V	16
199434	60	1394	MUC1-VI	17
199434	60	612	MUC1/X	20
199434	60	3078	MUC1/SEC	102
199434	60	741	MUC1/Z	103
199434	60	204	MUC1-X	107
199435	61	1540	MUC1	3
199435	61	694	MUC1/Y	10
199435	61	466	MUC1-II	11
199435	61	419	MUC1-IV	14
199435	61	1435	MUC1-VI	17
199435	61	653	MUC1/X	20
199435	61	782	MUC1/Z	103
199436	62	1582	MUC1	3
199436	62	736	MUC1/Y	10
199436	62	508	MUC1-II	11
199436	62	786	MUC1-V	16
199436	62	1477	MUC1-VI	17
199436	62	695	MUC1/X	20
199436	62	824	MUC1/Z	103
199437	63	1586	MUC1	3
199437	63	740	MUC1/Y	10

199437	63	512	MUC1-II	11
199437	63	790	MUC1-V	16
199437	63	1481	MUC1-VI	17
199437	63	699	MUC1/X	20
199437	63	828	MUC1/Z	103
199438	64	1594	MUC1	3
199438	64	520	MUC1-II	11
199438	64	798	MUC1-V	16
199438	64	1489	MUC1-VI	17
199438	64	707	MUC1/X	20
199438	64	836	MUC1/Z	103
199439	65	1606	MUC1	3
199440	66	1617	MUC1	3
199441	67	1622	MUC1	3
199441	67	1517	MUC1-VI	17
199442	68	1630	MUC1	3
199442	68	833	MUC1-V	16
199442	68	1525	MUC1-VI	17
199443	69	1635	MUC1	3
199443	69	514	MUC1-IV	14
199443	69	1530	MUC1-VI	17
199444	70	141	MUC1/Y	10
199444	70	244	MUC1-IX	106
199445	71	174	MUC1-II	11
199445	71	175	MUC1/Z	103
199446	72	297	MUC1-II	11
199447	73	49	MUC1-III	12
199448	74	3171	MUC1/SEC	102
199448	74	298	MUC1-X	107
199449	75	3279	MUC1/SEC	102
199449	75	407	MUC1-X	107
199450	76	559	MUC1-X	107
199451	77	160	MUC1-IV	14
199452	78	1134	MUC1/SEC	102
199452	78	65	MUC1-VIII	105
199453	79	1269	MUC1/SEC	102
199453	79	202	MUC1-VII	105
199454	80	455	MUC1-V	16
199455	81	1776	MUC1-VI	17
199456	82	115	MUC1-VII	18
199456	82	58	MUC1/A	100
199456	82	99	MUC1/REP	101
199456	82	116	MUC1-IX	106
199457	83	175	MUC1/X	20
199458	84	1132	MUC1	3
199458	84	286	MUC1/Y	10
199458	84	1027	MUC1-VI	17
199458	84	245	MUC1/X	20
199458	84	2488	MUC1/SEC	102
199458	84	374	MUC1/Z	103
199458	84	389	MUC1-IX	106
199459	85	122	MUC1/D	21
199460	86	85	MUC1/A	100

199460	86	126	MUC1/REP	101
199460	86	1332	MUC1/SEC	102
199461	87	115	MUC1	3
199461	87	82	MUC1-II	11
199461	87	130	MUC1-VI	17
199461	87	83	MUC1/X	20
199461	87	94	MUC1/A	100
199461	87	135	MUC1/REP	101
199461	87	1341	MUC1/SEC	102
199461	87	83	MUC1/Z	103
199462	88	147	MUC1	3
199462	88	81	MUC1/Y	10
199462	88	114	MUC1-II	11
199462	88	162	MUC1-VI	17
199462	88	183	MUC1-VII	18
199462	88	115	MUC1/X	20
199462	88	126	MUC1/A	100
199462	88	167	MUC1/REP	101
199462	88	1373	MUC1/SEC	102
199462	88	115	MUC1/Z	103
199462	88	154	MUC1/C	104
199462	88	306	MUC1-VIII	105
199462	88	184	MUC1-IX	106
199463	89	188	MUC1	3
199463	89	122	MUC1/Y	10
199463	89	155	MUC1-II	11
199463	89	203	MUC1-VI	17
199463	89	224	MUC1-VII	18
199463	89	156	MUC1/X	20
199463	89	167	MUC1/A	100
199463	89	208	MUC1/REP	101
199463	89	1414	MUC1/SEC	102
199463	89	156	MUC1/Z	103
199463	89	347	MUC1-VIII	105
199463	89	225	MUC1-IX	106
199464	90	207	MUC1	3
199464	90	222	MUC1-VI	17
199464	90	243	MUC1-VII	18
199464	90	186	MUC1/A	100
199464	90	227	MUC1/REP	101
199464	90	1433	MUC1/SEC	102
199464	90	366	MUC1-VIII	105
199465	91	710	MUC1	3
199465	91	109	MUC1-V	16
199465	91	605	MUC1-VI	17
199465	91	1816	MUC1/SEC	102
199466	92	938	MUC1	3
199466	92	42	MUC1-IV	14
199466	92	337	MUC1-V	16
199466	92	833	MUC1-VI	17
199466	92	2044	MUC1/SEC	102
199467	93	987	MUC1	3
199467	93	228	MUC1-II	11



199467	93	91	MUC1-IV	14
199467	93	386	MUC1-V	16
199467	93	882	MUC1-VI	17
199467	93	2093	MUC1/SEC	102
199467	93	229	MUC1/Z	103
199468	94	1006	MUC1	3
199468	94	160	MUC1/Y	10
199468	94	247	MUC1-II	11
199468	94	110	MUC1-IV	14
199468	94	405	MUC1-V	16
199468	94	901	MUC1-VI	17
199468	94	2112	MUC1/SEC	102
199468	94	248	MUC1/Z	103
199468	94	263	MUC1-IX	106
199469	95	2466	MUC1/SEC	102
199470	96	1281	MUC1	3
199470	96	435	MUC1/Y	10
199470	96	82	MUC1-III	12
199470	96	487	MUC1-V	16
199470	96	1176	MUC1-VI	17
199470	96	394	MUC1/X	20
199470	96	523	MUC1/Z	103
199470	96	538	MUC1-IX	106
199471	97	3292	MUC1/SEC	102
199471	97	420	MUC1-X	107

What is claimed is:

- 5           1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding mucin 1, transmembrane, wherein said compound specifically hybridizes with said nucleic acid molecule encoding mucin 1, transmembrane and inhibits the expression of mucin 1, transmembrane.
- 10          2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 23, 24, 25,  
26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42,  
15       43, 44, 45, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59,  
60, 61, 62, 64, 66, 67, 68, 69, 72, 74, 75, 76, 78, 79, 80, 81,  
88, 89, 90, 91, 93, 94, 96, 97, 98 or 99.
4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside  
20       linkage.
5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 25       7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. The compound of claim 8 wherein the modified  
30       nucleobase is a 5-methylcytosine.
10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of  
35       an active site on a nucleic acid molecule encoding mucin 1, transmembrane.
12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

-95-

13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.

5 15. A method of inhibiting the expression of mucin 1, transmembrane in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of mucin 1, transmembrane is inhibited.

10 16. A method of treating an animal having a disease or condition associated with mucin 1, transmembrane comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of mucin 1, transmembrane is inhibited.

15 17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

18. The method of claim 16 wherein the disease or disorder is an inflammatory disorder.

20 19. The compound of claim 1 targeted to a nucleic acid molecule encoding mucin 1, transmembrane, wherein said compound specifically hybridizes with and differentially inhibits the expression of one of the variants of mucin 1, transmembrane relative to the remaining variants of of mucin 1, transmembrane.

25 20. The compound of claim 19 targeted to a nucleic acid molecule encoding of mucin 1, transmembrane, wherein said compound hybridizes with and specifically inhibits the expression of a variant of of mucin 1, transmembrane, wherein said variant is selected from the group consisting of MUC1, MUC1/Y, MUC1/X, MUC1/D, MUC1/A, MUC1/REP, MUC1/SEC, MUC1/Z, MUC1/C, MUC1-II, MUC1-III, MUC1-IV, MUC1-V, MUC1-VI, MUC1-VII, 30 MUC1-VIII, MUC1-IX and MUC1-X.

## SEQUENCE LISTING

<110> Kenneth W. Dobie  
 Susan J. Myers  
 Isis Pharmaceuticals, Inc.

<120> ANTISENSE MODULATION OF MUCIN 1, TRANSMEMBRANE EXPRESSION

<130> RTSP-0442

<150> 10/029,517  
 <151> 2001-12-20

<160> 107

<210> 1  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1  
 tccgtcatcg ctctcaggg 20

<210> 2  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2  
 atgcattctg cccccaagga 20

<210> 3  
 <211> 1721  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (58)...(1605)

<400> 3  
 gaattccctg gctgcttgaa tctgttctgc ccctcccca cccatttcac caccacc 57

atg aca cag ggc acc cag tct cct ttc ttc ctg ctg ctg ctc aca 105

Met	Thr	Pro	Gly	Thr	Gln	Ser	Pro	Phe	Phe	Leu	Leu	Leu	Leu	Thr		
1				5					10					15		
gtg	ctt	aca	gtt	gtt	aca	ggg	tct	ggg	cat	gca	agc	tct	acc	cca	ggg	153
Val	Leu	Thr	Val	Val	Thr	Gly	Ser	Gly	His	Ala	Ser	Ser	Thr	Pro	Gly	
			20					25					30			
gga	gaa	aag	gag	act	tcg	gct	acc	cag	aga	agt	tca	gtg	ccc	agc	tct	201
Gly	Glu	Lys	Glu	Thr	Ser	Ala	Thr	Gln	Arg	Ser	Ser	Val	Pro	Ser	Ser	
		35					40					45				
act	gag	aag	aat	gct	gtg	agt	atg	acc	agc	agc	gta	ctc	tcc	agc	cac	249
Thr	Glu	Lys	Asn	Ala	Val	Ser	Met	Thr	Ser	Ser	Val	Leu	Ser	Ser	His	
		50				55					60					
agc	ccc	ggg	tca	ggc	tcc	tcc	acc	act	cag	gga	cag	gat	gtc	act	ctg	297
Ser	Pro	Gly	Ser	Gly	Ser	Ser	Thr	Thr	Gln	Gly	Gln	Asp	Val	Thr	Leu	
		65			70				75					80		
gcc	ccg	gcc	acg	gaa	cca	gct	tca	ggg	tca	gct	gcc	acc	tgg	gga	cag	345
Ala	Pro	Ala	Thr	Glu	Pro	Ala	Ser	Gly	Ser	Ala	Ala	Thr	Trp	Gly	Gln	
			85					90					95			
gat	gtc	acc	tcg	gtc	cca	gtc	acc	agg	cca	gcc	ctg	ggc	tcc	acc	acc	393
Asp	Val	Thr	Ser	Val	Pro	Val	Thr	Arg	Pro	Ala	Leu	Gly	Ser	Thr	Thr	
			100					105					110			
cog	cca	gcc	cac	gat	gtc	acc	tca	gcc	ccg	gac	aac	aag	cca	gcc	ccg	441
Pro	Pro	Ala	His	Asp	Val	Thr	Ser	Ala	Pro	Asp	Asn	Lys	Pro	Ala	Pro	
		115					120					125				
ggc	tcc	acc	gcc	ccc	cca	gcc	cac	ggg	gtc	acc	tcg	gcc	ccg	gac	acc	489
Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr	
		130				135					140					
agg	ccg	ccc	ccg	ggc	tcc	acc	gcc	ccc	cca	gcc	cac	ggg	gtc	acc	tcg	537
Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Pro	Ala	His	Gly	Val	Thr	Ser	
		145			150				155					160		
gcc	ccg	gac	acc	agg	ccg	ccc	ccg	ggc	tcc	acc	gag	ccc	gca	gcc	cac	585
Ala	Pro	Asp	Thr	Arg	Pro	Pro	Pro	Gly	Ser	Thr	Ala	Pro	Ala	Ala	His	
			165					170					175			
ggg	gtc	acc	tcg	gcc	ccg	gac	acc	agg	ccg	gcc	ccg	ggc	tcc	acc	gcc	633
Gly	Val	Thr	Ser	Ala	Pro	Asp	Thr	Arg	Pro	Ala	Pro	Gly	Ser	Thr	Ala	
			180					185				190				
ccc	cca	gcc	cat	ggg	gtc	acc	tcg	gcc	ccg	gac	aac	agg	ccc	gcc	ttg	681
Pro	Pro	Ala	His	Gly	Val	Thr	Ser	Ala	Pro	Asp	Asn	Arg	Pro	Ala	Leu	
		195					200					205				
gcg	tcc	acc	gcc	cct	cca	gtc	cac	aat	gtc	acc	tcg	gcc	tca	ggc	tct	729
Ala	Ser	Thr	Ala	Pro	Pro	Val	His	Asn	Val	Thr	Ser	Ala	Ser	Gly	Ser	
		210				215					220					
gca	tca	ggc	tca	gct	tct	act	ctg	gtg	cac	aac	ggc	acc	tct	gcc	agg	777
Ala	Ser	Gly	Ser	Ala	Ser	Thr	Leu	Val	His	Asn	Gly	Thr	Ser	Ala	Arg	
		225			230				235					240		

gct acc aca acc cca gcc agc aag agc act cca ttc tca att ccc agc Ala Thr Thr Thr Pro Ala Ser Lys Ser Thr Pro Phe Ser Ile Pro Ser	825
245 250 255	
cac cac tct gat act cct acc acc ctt gcc agc cat agc acc aag act His His Ser Asp Thr Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr	873
260 265 270	
gat gcc agt agc act cac cat agc acg gta cct cct ctc acc tcc tcc Asp Ala Ser Ser Thr His His Ser Thr Val Pro Pro Leu Thr Ser Ser	921
275 280 285	
aat cac agc act tct ccc cag ttg tot act ggg gtc tct ttc ttt ttc Asn His Ser Thr Ser Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe	969
290 295 300	
ctg tct ttt cac att tca aac ctc cag ttt aat tcc tct ctg gaa gat Leu Ser Phe His Ile Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp	1017
305 310 315 320	
ccc agc acc gac tac tac caa gag ctg cag aga gac att tct gaa atg Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met	1065
325 330 335	
ttt ttg cag att tat aaa caa ggg ggt ttt ctg ggc ctc tcc aat att Phe Leu Gln Ile Tyr Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile	1113
340 345 350	
aag ttc agg cca gga tct gtg gtg gta caa ttg act ctg gcc ttc cga Lys Phe Arg Pro Gly Ser Val Val Gln Leu Thr Leu Ala Phe Arg	1161
355 360 365	
gaa ggt acc atc aat gtc cac gac gtg gag aca cag ttc aat cag tat Glu Gly Thr Ile Asn Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr	1209
370 375 380	
aaa acg gaa gca gcc tct cga tat aac ctg acg atc tca gac gtc agc Lys Thr Glu Ala Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser	1257
385 390 395 400	
gtg agt gat gtg cca ttt cct ttc tct gcc cag tct ggg gct ggg gtg Val Ser Asp Val Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val	1305
405 410 415	
cca ggc tgg ggc atc gcg ctg ctg gtg ctg gtc tgt gtt ctg gtt gcg Pro Gly Trp Gly Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala	1353
420 425 430	
ctg gcc att gtc tat ctc att gcc ttg gct gtc tgt cag tgc cgc cga Leu Ala Ile Val Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg	1401
435 440 445	
aag aac tac ggg cag ctg gac atc ttt cca gcc cgg gat acc tac cat Lys Asn Tyr Gly Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His	1449
450 455 460	
cct atg agc gag tac ccc acc tac cac acc cat ggg cgc tat gtg ccc Pro Met Ser Glu Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro	1497
465 470 475 480	

cct agc agt acc gat cgt agc ccc tat gag aag gtt tct gca ggt aat 1545  
 Pro Ser Ser Thr Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn  
 485 490 495

ggt ggc agc agc ctc tct tac aca aac cca gca gtg gca gcc act tct 1593  
 Gly Gly Ser Ser Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser  
 500 505 510

gcc aac ttg tag gggcacgtcg ccctctgagc tgagtggcca gccagtgcc 1645  
 Ala Asn Leu  
 515

ttccactcca ctccagggtc tctgggccag tctctctggg agccccacc acaaaccttc 1705  
 ccaggcatgg aattcc 1721

<210> 4  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> PCR Primer

<400> 4  
 tgactctggc ctcccgagaa 20

<210> 5  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5  
 gctgcttccg ttttatactg attg 24

<210> 6  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> PCR Probe

<400> 6  
 taccatcaat gtccacgacg tggagaca 28

<210> 7  
 <211> 19  
 <212> DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR Primer

&lt;400&gt; 7

gaaggtgaag gtcggagtc

19

&lt;210&gt; 8

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR Primer

&lt;400&gt; 8

gaagatggtg atgggatttc

20

&lt;210&gt; 9

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; PCR Probe

&lt;400&gt; 9

caagcttccc gttctcagcc

20

&lt;210&gt; 10

&lt;211&gt; 759

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(759)

&lt;400&gt; 10

atg	aca	cog	ggc	acc	cag	tct	cct	ttc	ttc	ctg	ctg	ctg	ctc	ctc	aca	48
Met	Thr	Pro	Gly	Thr	Gln	Ser	Pro	Phe	Phe	Leu	Leu	Leu	Leu	Leu	Thr	
1				5						10				15		

gtg	ctt	aca	ggt	tct	ggt	cat	gca	agc	tct	acc	cca	ggt	gga	gaa	aag	96
Val	Leu	Thr	Gly	Ser	Gly	His	Ala	Ser	Ser	Thr	Pro	Gly	Gly	Glu	Lys	
			20					25					30			

gag	act	tcg	gct	acc	cag	aga	agt	tca	gtg	ccc	agc	tct	act	gag	aag	144
Glu	Thr	Ser	Ala	Thr	Gln	Arg	Ser	Ser	Val	Pro	Ser	Ser	Thr	Glu	Lys	
			35				40					45				



aat gct ttt aat tcc tct ctg gaa gat ccc agc acc gac tac tac caa Asn Ala Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln 50 55 60	192
gag ctg cag aga gac att tct gaa atg ttt ttg cag att tat aaa caa Glu Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln 65 70 75 80	240
ggg ggt ttt ctg ggc ctc tcc aat att aag ttc agg cca gga tct gtg Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser Val 85 90 95	288
gtg gta caa ttg act ctg gcc ttc cga gaa ggt acc atc aat gtc cac Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn Val His 100 105 110	336
gac atg gag aca cag ttc aat cag tat aaa acg gaa gca gcc tct cga Asp Met Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser Arg 115 120 125	384
tat aac ctg acg atc tca gac gtc agc gtg agt gat gtg cca ttt cct Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe Pro 130 135 140	432
ttc tct gcc cag tct ggg gct ggg gtg cca ggc tgg gcc atc gcg ctg Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala Leu 145 150 155 160	480
ctg gtg ctg gtc tgt gtt ctg gtt gcg ctg gcc att gtc tat ctc att Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu Ile 165 170 175	528
gcc ttg gct gtc tgt cag tgc cgc cga aag aac tac ggg cag ctg gac Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu Asp 180 185 190	576
atc ttt cca gcc cgg gat acc tac cat cct atg agc gag tac ccc acc Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro Thr 195 200 205	624
tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc gat cgt agc Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg Ser 210 215 220	672
ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc ctc tct tac Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr 225 230 235 240	720
aca aac cca gca gtg gca gcc act tct gcc aac ttg tag Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu 245 250	759

&lt;210&gt; 11

&lt;211&gt; 543

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (25)...(531)

&lt;400&gt; 11

ctccccaccc atttcaccac cacc atg aca ccg ggc acc cag tct cct ttc 51  
 Met Thr Pro Gly Thr Gln Ser Pro Phe  
 1 5

ttc ctg ctg ctg ctc ctc aca gtg ctt aca gtt gtt aca ggt tct ggt 99  
 Phe Leu Leu Leu Leu Thr Val Leu Thr Val Val Thr Gly Ser Gly  
 10 15 20 25

cat gca agc tct acc cca ggt gga gaa aag gag act tcg gct acc cag 147  
 His Ala Ser Ser Thr Pro Gly Gly Glu Lys Glu Thr Ser Ala Thr Gln  
 30 35 40

aga agt tca gtg ccc agc tct act gag aag aat gct ttg tct act ggg 195  
 Arg Ser Ser Val Pro Ser Ser Thr Glu Lys Asn Ala Leu Ser Thr Gly  
 45 50 55

gtc tct ttc ttt ttc ctg tct ttt cac att tca aac ctc cag ttt aat 243  
 Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu Gln Phe Asn  
 60 65 70

tcc tct ctg gaa gat ccc agc acc gac tac tac caa gag ctg cag aga 291  
 Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu Leu Gln Arg  
 75 80 85

gac att tct gaa atg gct gtc tgt cag tgc cgc cga aag aac tac ggg 339  
 Asp Ile Ser Glu Met Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly  
 90 95 100 105

ctg ctg gac atc ttt cca gcc cgg gat acc tac cat cct atg agc gag 387  
 Leu Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu  
 110 115 120

tac ccc acc tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc 435  
 Tyr Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr  
 125 130 135

gat cgt agc ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc 483  
 Asp Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser  
 140 145 150

ctc tct tac aca aac cca gca gtg gca gcc act tct gcc aac ttg tag 531  
 Leu Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu  
 155 160 165

gggcacgtcg cc 543

&lt;210&gt; 12

&lt;211&gt; 122

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> exon:exon junction

<222> (58)...(59)

<223> exon 4:exon 6

```

<400> 12
atgtttttgc agatttataa acaagggggt ttcttgggcc tctccaatat taagttcagt    60
gagtgatgtg caatttcctt tctctgccca gtctggggct ggggtgccag gctggggcat    120
cg                                         122

```

<210> 13

<211> 000

<212> DNA

<213> Homo sapiens

<220>

<400> 13

000

<210> 14

<211> 577

<212> DNA

<213> Homo sapiens

<220>

<221> exon:exon junction

<222> (169)...(170)

<223> exon 3c:exon 6b

```

<400> 14
cgtgtcgcga ctgtcacct cctccaatca cagcacttct cccagttgt ctactgggggt    60
ctcttttctt ttctgtcttt ttcacatttc aaacctccag ttttaattct ctctggaaga    120
tcccagcacc gactactacc aagagctgca gagagacatt tctgaaatgt ctggggctgg    180
gggtgccagg tggggcatcg cgctgctggt gctggctctgt gttctgggtg cgctggccat    240
tgtctatctc attgccttgg ctgtctgtca gtgcgcgcga aagaactacg gccagctgga    300
catctttcca gcccgggata cctaccatcc tatgagcgag tacccaacct accacaccca    360
tgggcgcctat gtgcccccta gcagtaacga tcgtagcccc tatgagaagg tttctgcagg    420
taatgtgtgc agcagcctct cttacacaaa ccagcagctg gcagccaact cttgcaactt    480
gtaggggcac gtcgcccgcg gagctgagta gccagccagt gccattccac tccactcagg    540
ttcttcaggg ccagagcccc tgcaccctgt ttgggct                                     577

```

<210> 15

<211> 000

<212> DNA

<213> Homo sapiens

<220>

<400> 15

000

<210> 16

<211> 981

<212> DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; exon:exon junction

&lt;222&gt; (464)...(465)

&lt;223&gt; exon 3b:exon 4

&lt;400&gt; 16

```

gggacaccag ggcggccccc ggctccacgg cccccccagc ccatggtgtc acctgggccc 60
oggacaaacg gccgcctctg ggctccacgg cccctccagt ccaacaatgtc acctgggccc 120
caggctctcg atcaggctca gcttctactc tggtgcacaa cagcaacctct gccagggcta 180
ccacaacccc agccagcaag agcaacctat tctcaattcc cagccaccac tctgatactc 240
ctacacacct tccacggcat agcaccgaag ctgatgccag tagcaactac catagcacgg 300
tacctctctc cactctctcc aatcaccgca cttctcccca gttgtctact ggggtctctt 360
tcttttttct gtctttttac atttcaaacc tccagtttaa tctctctctg gaagatccca 420
gcacggacta ctaccaagag ctgcagagag acattttctga aatgtgagtg atgtgccatt 480
tcctttctct gccacgtctg gggctggggg gccaggctgg gccatcgccg tgctgggtgt 540
ggctctgtgt ctggttgccg tggccattgt ctatctcatt gccttggtctg tctgtcagtg 600
ccgcggaag aactacgggc agctggacat ctttccagcc cgggataacct accatcccat 660
gagcagtagt cccacctacc aaccatggg cgctatgtgc cccctagcag taccgatcgt 720
agccctcatg agacagggtt ctgcaggtaa tgggtggcag agctctctta cacaacccag 780
cagtgccagc cacttctgcc aacttgtagg ggcacgcttc cgctgacctg agtgccccagc 840
cagtgccatt caacttccac tcagggttct tcaggggcca gagccctgca cctgttttgc 900
cctggtgagc tggactccaa ggtgggctgt cacagcctct tcaaggcccc acaattcttc 960
gacatctca ggtgtggaag c

```

&lt;210&gt; 17

&lt;211&gt; 1804

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (73)...(1500)

&lt;400&gt; 17

```

cgctccacct ctcaagcagc cagcgccctg ctgaatctgt tctgccccct cccccccat 60
ttcaccacca cc atg aca ccg ggc acc cag tct cct ttc ttc ctg ctg ctg 111
          Met Thr Pro Gly Thr Gln Ser Pro Phe Leu Leu Leu
          1              5              10

ctc ctc aca gtg ctt aca gtt gtt aca ggt tct ggt cat gca agc tct 159
Leu Leu Thr Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser
          15              20              25

acc cca ggt gga gaa aag gag act tog gct acc cag aga agt tca gtg 207
Thr Pro Gly Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val
          30              35              40              45

ccc agc tct act gag aag aat gct gtg agt atg acc agc agc gta ctc 255
Pro Ser Ser Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu
          50              55              60

tcc agc cac agc ccc ggt tca ggc tcc acc act cag gga cag gat 303
Ser Ser His Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp
          65              70              75

```

gtc act ctg gcc ccg gcc acg gaa cca gct tca ggt tca gct gcc acc Val Thr Leu Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr 80 85 90	351
tgg gga cag gat gtc acc tcg gtc cca gtc acc agg cca gcc ctg ggc Trp Gly Gln Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly 95 100 105	399
tcc acc acc ccg cca gcc cac gat gtc acc tca gcc ccg gac aac aag Ser Thr Thr Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys 110 115 120 125	447
cca gcc ccg ggc tcc acc gcc ccc cca gcc cac ggt gtc acc tcg gcc Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala 130 135 140	495
ccg gac acc agg ccg gcc ccg ggc tcc acc gcc ccc cca gcc cat ggt Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly 145 150 155	543
gtc acc tcg gcc ccg gac aac agg ccc gcc ttg ggc tcc acc gcc cct Val Thr Ser Ala Pro Asp Asn Arg Pro Ala Leu Gly Ser Thr Ala Pro 160 165 170	591
cca gtc cac aat gtc acc tcg gcc tca ggc tct gca tca ggc tca gct Pro Val His Asn Val Thr Ser Ala Ser Gly Ser Ala Ser Gly Ser Ala 175 180 185	639
tct act ctg gtg cac aac ggc acc tct gcc agg gct acc aca acc cca Ser Thr Leu Val His Asn Gly Thr Ser Ala Arg Ala Thr Thr Thr Pro 190 195 200 205	687
gcc agc aag agc act cca ttc tca att ccc agc cac cac tct gat act Ala Ser Lys Ser Thr Pro Phe Ser Ile Pro Ser His His Ser Asp Thr 210 215 220	735
cct acc acc ctt gcc agc cat agc acc aag act gat gcc agt agc act Pro Thr Thr Leu Ala Ser His Ser Thr Lys Thr Asp Ala Ser Ser Thr 225 230 235	783
cac cat agc acg gta cct cct ctc acc tcc tcc aat cac agc act tct His His Ser Thr Val Pro Pro Leu Thr Ser Ser Asn His Ser Thr Ser 240 245 250	831
ccc cag ttg tct act ggg gtc tct ttc ttt ttc ctg tct ttt cac att Pro Gln Leu Ser Thr Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile 255 260 265	879
tca aac ctc cag ttt aat tcc tct ctg gaa gat ccc agc acc gac tac Ser Asn Leu Gln Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr 270 275 280 285	927
tac caa gag ctg cag aga gac att tct gaa atg ttt ttg cag att tat Tyr Gln Glu Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr 290 295 300	975
aaa caa ggg ggt ttt ctg ggc ctc tcc aat att aag ttc agg cca gga Lys Gln Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly	1023

11

305	310	315	
tct gtg gtg gta caa ttg act ctg gcc ttc cga gaa ggt acc atc aat			1071
Ser Val Val Val Gln Leu Thr	Leu Ala Phe Arg Gly Thr Ile Asn		
320	325	330	
gtc cac gac gtg gag aca cag ttc aat cag tat aaa acg gaa gca gcc			1119
Val His Asp Val Glu Thr	Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala		
335	340	345	
tct cga tat aac ctg acg atc tca gac gtc agc gtg agt gat gtg cca			1167
Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro			
350	355	360	365
ttt cct ttc tct gcc cag tct ggg gct ggg gtg cca ggc tgg ggc atc			1215
Phe Pro Phe Ser Ala Gln Ser Gly Ala	Gly Val Pro Gly Trp Gly Ile		
370	375	380	
gcg ctg ctg gtg ctg gtc tgt gtt ctg gtt gcg ctg gcc att gtc tat			1263
Ala Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr			
385	390	395	
ctc att gcc ttg gct gtc tgt cag tgc cgc cga aag aac tac ggg cag			1311
Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln			
400	405	410	
ctg gac atc ttt cca gcc cgg gat acc tac cat cct atg agc gag tac			1359
Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr			
415	420	425	
ccc acc tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc gat			1407
Pro Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp			
430	435	440	445
cgt agc ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc ctc			1455
Arg Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu			
450	455	460	
tct tac aca aac cca gca gtg gca gcc act tct gcc aac ttg tag			1500
Ser Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu			
465	470	475	
gggcacgtgc ccoctgagc tgagtgccca gccagtgcca ttccactcca ctcaggttct			1560
tcagggccag agccctcgca cctgttttgg gctggtgagc tgggagttca ggtgggtctgc			1620
tcacacgcgtc cttcagagggc ccaccaatt tctcggacac ttctcagtggt gtggaagctc			1680
atgtggggccc ctgaggctca tgcctgggaa gtgttgtggt gggggctccc aggaggactg			1740
gccagagag cctgagata gcggggatcc tgaactggac tgaataaaac gtggtctccc			1800
actg			1804
<210> 18			
<211> 572			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> CDS			
<222> (67)...(572)			

<400> 18  
 acctctcaag cagccagcgc ctgcctgaat ctgttctgcc ccctccccac ccatttcacc 60  
 accacc atg aca cag gcc acc cag tct cct ttc ttc ctg ctg ctg ctc 108  
     Met Thr Pro Gly Thr Gln Ser Pro Phe Leu Leu Leu Leu  
         1                    5                    10

ctc aca gtg ctt aca gct acc aca gcc cct aaa ccc gca aca gtt gtt 156  
 Leu Thr Val Leu Thr Ala Thr Thr Ala Pro Lys Pro Ala Thr Val Val 15  
                     20                    25                    30

acg ggt tct ggt cat gca agc tct acc cca ggt gga gaa aag gag act 204  
 Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly Gly Glu Lys Glu Thr 35  
                     35                    40                    45

tgg gct acc cag aga agt tca gtg ccc agc tct act gag aag aat gct 252  
 Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser Thr Glu Lys Asn Ala 50  
                     50                    55                    60

gtg agt atg acc agc agc gta ctc tcc agc cac agc ccc ggt tca gcc 300  
 Val Ser Met Thr Ser Ser Val Leu Ser Ser His Ser Pro Gly Ser Gly 65  
                     65                    70                    75

tcc tcc acc act cag gga cag gat gtc act ctg gcc ccg gcc acg gaa 348  
 Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu Ala Pro Ala Thr Glu 80  
                     80                    85                    90

cca gct tca ggt tca gct gcc acc tgg gga cag gat gtc acc tgg gtc 396  
 Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln Asp Val Thr Ser Val 95  
                     95                    100                    105                    110

cca gtc acc agg cca gcc ctg gcc tcc acc acc ccg cca gcc cac gat 444  
 Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr Pro Pro Ala His Asp 115  
                     115                    120                    125

gtc acc tca gcc ccg gac aac aag cca gcc ccg gcc tcc acc gcc ccc 492  
 Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro Gly Ser Thr Ala Pro 130  
                     130                    135                    140

caa gcc cac ggt gtc acc tgg gcc ccg gac acc agg ccg gcc ccg gcc 540  
 Gln Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly 145  
                     145                    150                    155

tcc acc gcc ccc caa gcc cac ggt gtc acc tc 572  
 Ser Thr Ala Pro Gln Ala His Gly Val Thr 160  
                     160

<210> 19  
 <211> 8186  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> unsure  
 <222> 6899  
 <223> unknown  
 <221> unsure

```

<222> 7155
<223> unknown

<221> unsure
<222> 7184
<223> unknown

<221> unsure
<222> 7957
<223> unknown

<221> intron
<222> (2997)...(3498)
<223> intron 1

<221> intron:exon junction
<222> (3498)...(3499)
<223> intron 1:exon 2

<221> exon
<222> (3508)...(3599)
<223> exon 2d

<221> exon:intron junction
<222> (3982)...(3983)
<223> exon 2a:intron 2a

<221> intron:exon junction
<222> (4205)...(4206)
<223> intron 2c:exon 3c

<221> intron:exon junction
<222> (4259)...(4260)
<223> intron 2d:exon 3d

<221> exon
<222> (4260)...(4328)
<223> exon 3d

<221> intron:exon junction
<222> (4632)...(4633)
<223> intron 3:exon 4

<221> exon
<222> (4914)...(5035)
<223> exon 5

<221> intron
<222> (5266)...(6293)
<223> intron 6

<400> 19
gaattcagaa ttttagaccc ttgtgccttg ggggccatcc tggagaccct gaggtctaa 60
ctacagccccc tcagccaacc acagaccctt ctctggctcc caaaaggagt tcagtccag 120
aggttggtca cccacccttc agggatgaga agttttcaag gggattactc caggcactaa 180
ccccaggaaa gatgacagca cattgccata aagttttggt tgttttctaa gccagtcaa 240
ctgctatttt tagggatttt cgggataggt gtggggaagt ggaaggaate ggcgagtaga 300
agagaagccc tgggaggggtg gaagttaggg atctagggga agtttgctg atttgggat 360
gggggtgggg gaggtgcttg atggagttaa gtgaaggata ggggtgctga gggaggatgc 420

```



ccgaagtcc	ccagaccga	cttactcag	gtggcagcg	cgacactcca	gtctataaaa	480
gatccgcgg	gatggagagc	caggaggcg	gggctgcc	tgaagtagcg	ggaggagcgg	540
ggggcgggg	ggcgagcgg	acgagtcaa	tattggcgg	ggaaaaaaca	acactgcacc	600
gogtccgtc	ctcccgccg	gcccggccc	ggatcccg	cccaacgcgc	tgaagcgcc	660
ccgacccgga	accgcggcg	ctggggagtt	gggttccact	tggaggccag	agagacttgg	720
ccgcgggaag	caaaaggaat	ggcaagggg	aggggggag	gagaacggga	gtttgoggag	780
tgcgaaggg	cgctttccga	cgcccgggcg	ttgcgcgcg	ttgctcttta	agtaactcaga	840
ctcgccggcg	cgagccgtcc	gcattggtgac	gogtgtccca	gcaacogaaac	tgaattggctg	900
tttcttgcca	atgcggggag	ttgaggtttg	gggcgcgcca	cctagctact	ogtgtttctc	960
ccggctcgtc	agttgggggg	ctccgcctc	ccgggcgcg	tcctggggcg	gctgaogtca	1020
gtgtcccca	ccccgcgaag	cgctgcccc	aagggtctcg	cgcaacaaca	agctggcctc	1080
ogggcgccgg	cgccggggcg	agagcggtgg	ttctctcgct	gctgatctga	tgcgctccaa	1140
tcocgtgctc	cgccgaagtg	tttttaagt	gttctttcca	acctgtgtct	ttggggctga	1200
gaactgttt	ctgaatacag	gcggaaactgc	ttcgtcgcc	ctagagcgac	gctgcagactg	1260
ggggaccocaa	gttccacgtg	ctgcgcgcg	ctgggtagcg	ttcctccctc	ogtgcactgc	1320
tgcgcacac	acctcttggc	ttgtcgccat	taogcaacta	acgtgtgctt	ttgcccccgc	1380
ctacgtgctc	acctgtcccc	aataccaactc	gccccccctc	aggtatgttc	ttgtctcgta	1440
aatcccaattc	tgtaacacca	octactctct	ggcgccgctc	ttttgttttt	gagagcgagc	1500
tttgcctctg	cgccacgggt	ggagtgcact	ggcgccgctg	cggtcactg	caactccgcg	1560
ctcccggttc	caagcgatct	ttctgctca	gctcctgag	tacgtggggg	tacagcgccc	1620
gccaaccgcg	tcggctcaatt	ttttagtatt	ttagtagaga	cgaggtttca	ccatcttggc	1680
gactcccttc	ttgaacccct	gacotttgtga	ttccactgcg	tcggccttcc	aaagtgtttg	1740
gattccggcg	gtgacgacgc	tgccacgcgat	ctgcctctta	agtaacataac	ggcccaacaca	1800
gaacgtgctc	aaactccccc	cccaagtttcc	aaagtcctct	cccaataacc	ctggtgcgcc	1860
ttccacatac	ctcagggacc	caaccgotta	gtcccatctc	ctccagacgc	caccacaacg	1920
ogtccgggag	tgcccccctc	taaagctccc	agccgtccac	catgtgtgct	gttccctccg	1980
ccctggccac	ggccagtacc	cttctctccc	gggcctgct	tcctctcgcg	gggctctgct	2040
gcctcaacta	ggcagcgctg	cccttactcc	ttccgcgcg	tcocagcgcg	ccctccagct	2100
tcggcgccga	gcccgcgaag	gctccgggtg	accaactag	ggcggggagg	gctccctggc	2160
agtggtggag	agtgccgaag	aaggacocct	gggttcaatg	gagcccaagt	ttactccctt	2220
aagtggaaat	ttcttccccc	actcctcctt	ggcttctccc	aaggaggga	ccagcctctg	2280
tggaaagtcc	ggctgggggg	gggactgtgg	gttccaggga	gaaocgggtg	tggaaocggga	2340
caggagagcg	ttagaagggt	ggggctattc	ogggaaagtg	tggggggagg	gagcccaaaa	2400
ctagcacocct	gtccactcat	tatccagccc	ttctatttct	cggcgctcct	gctccagtgg	2460
accocggggg	ggcgagggag	tggaagtggga	gacctagggg	ttgggttccc	ttctgtctg	2520
tacagggaact	cgacctagct	ggctttgttc	cccatcccca	cgtagtgtgt	ttccctgagg	2580
ctaaaactag	agcccgagg	ccccaagttc	cgactgccc	ctcccccctc	ccocggagcc	2640
agggagtgg	tggtgaaagg	gggaggccag	ctggagaaca	aacgggtagt	cagggggttg	2700
agcgattaga	gcocttgtac	octaccaggg	aatggttggg	gaggaggagg	aagaggttag	2760
aggttagggga	ggggcggggg	ttttgtccac	tgtaacotcg	tcgtctggcc	tagggcgggc	2820
ggcgggggag	tggggggaac	ggataaaagc	ggtagggcgc	tgtgcccgct	ccacctctca	2880
agcagccagc	gctgcctcta	atctgtttct	cccccctccc	accattttca	ccacacacat	2940
gacacccggc	accagactctc	ctttcttctc	gctgctgctc	ctcacagtgc	ttaaaggttg	3000
ggggccagcag	gtggggagtg	ggctgcocgt	cttaggtgtg	cttcgtgtgtc	ttctgtgtgg	3060
ttttgctccc	tgccagatgg	caccatgaag	ttaaagtgag	aattgcagac	agagcgtcgc	3120
ctgtctgtgc	cagaaggagg	gagaggctaa	ggacaggctg	agaagagttg	ccccaacccc	3180
tgagagtggg	taccaggggc	aagcaaatgt	cctgtagaga	agcttagggg	gaagagagta	3240
gggagaggga	aggtcttaaga	ggggaagaaa	tgccaggggc	atgagccaag	cagggggtac	3300
agagagaaag	aggtctgtgc	agggaaaggag	gcttccaacc	cagggggtac	tgaggtctgc	3360
cactccccag	ttcctctggg	attattttct	tggtggccag	agcttataat	ttctcttctg	3420
ttctattttt	octtcaataa	gaaccaaccc	tatgacttta	acttctatta	gttacaacaa	3480
ccctcaaac	cgcaacagtt	gttacaggtt	ctggtatgc	aagctctacc	ccaggttgag	3540
aaaagagac	ttcggctacc	cagagaagtt	cagtcgccag	ctctactgag	agaagtgtgt	3600
tgagtattgac	cagcagctga	ctctccagcc	acagcccgcc	ttcagggtcc	ttccacactc	3660
agggacagga	tgtaactctg	gcccgcgcca	cggaaaccga	ttcaggttca	gctgcacact	3720
ggggacagga	tgtaactctg	gtccagctca	ccaggccagc	cctgggctcc	accacccccc	3780
cagcccaaga	tgtaactctc	gcccgggaca	acaagccagc	cccgggctcc	accgcccccc	3840
cagcccaaga	tgtaactctg	gcccgggaca	acaggccggc	cccgggctcc	accgcccccc	3900
cagcccaatg	tgtaactctg	gcccgggaca	acaggccggc	cttgggctcc	accgcccccc	3960

cagtcacaaa	tgctcacctcg	gcttcagggt	ctgcacatcagg	ctcagcttct	actctggtgc	4020
acaacggcac	ctctgccagg	gctacccaaa	ccccagccag	caagagcact	ccattctcaa	4080
ttccagccca	ccaactctgat	actctaccca	cccttgccag	ccatagcacc	aagacttgatg	4140
ccagtagcac	tcaccatacct	acggtagctc	ctctcacctc	ctccaatcac	agcaactctc	4200
cccagttgtc	tactgggggtc	ttctttcttt	tcctgtcttt	tcacatttca	aaacctccagt	4260
ttaatctctc	tcgtggaagt	cccagcacog	actactacca	agagctgcag	agagacattt	4320
ctgaaatggg	gagtatccgg	ctttctcttc	ccatgtctcc	ctgaagcagc	catcagaact	4380
gtccacaccc	tttgcatcaa	cccagagtc	tttccctctc	acccagattt	ctgtcagatt	4440
ataaaacagg	gggtttttctg	ggcctctcca	atattaagtt	caggtacagt	ttgggtgttg	4500
gaccagagtt	gggtggttga	gggttggttg	tggtgcatga	ccgtaggagg	gactgtgtgca	4560
cttaaatgct	ggggaagagt	gctgagccag	agctgggacc	ctgtgctgaa	tgctccattt	4620
ccctgtgacc	agggccaggt	ctgtggtggt	acaattgact	ctggccttcc	gagaaggatc	4680
atataacctg	acgatctcag	agacacagtt	caatcagtat	aaaacgggaag	cagcctctcg	4740
catgcogggg	ccctctctct	acgtcagcgg	tgaggctact	tccttggctg	cagccagcac	4800
cggtgggggt	gctctctctg	ttccagtgct	gggtcccgcg	ttttctctta	tgctggcgag	4860
tggtgccattt	cccttctctg	ggagactgcc	ctgaccaactg	ctttctcttt	tagtgagtga	4920
gctggtgctg	gtctgtgtct	ccagctctgg	ggctggggtg	ccagctgtgg	ctgtccgcgt	4980
tgagtcctct	ggccctgctg	agagccccc	ggccatttgt	tatctcatct	ccctgtgtgag	5040
ctcctatctc	cccaggctgt	ctgtcagtcg	ggtagaaggc	actccatggc	ctgtccataac	5100
tttccagccc	gggataccta	ccatcctatg	agcgagtcac	ccactcggca	gctggacatt	5160
cgctatgtgc	ccctcagcag	tacogtatgt	agccctctatg	agaaggtgag	ctggccctgg	5220
caggcccgagg	gaagcagagg	gtttggctgg	gcaaggattc	tgaagggggt	acttggaana	5280
cccacagagc	ttggaagtag	tgagaagtgg	cgtagaagtga	caggggggag	ctctggccag	5340
gatgaggggc	agaggtcaga	ggagttttgg	gggacagccc	tgaggaggaga	ctatggaaga	5400
aaagggcgct	aaaggggagt	ggccccaactg	ccagaattcc	taaaaagact	atctggcgctc	5460
cacattctac	ctggctggcg	ctggctgaac	tggtgccaco	gtggcagttt	tgttttgttt	5520
tgcttttttt	caccagagag	caaaaatgggt	ggagccaatc	ggccagggga	gcctctccgc	5580
aggagtccag	gggtgagcct	ctgtgatccc	ttaatcaatc	tcctaggaat	ggagggtaga	5640
cggagaaaag	ctgtggcatag	ggggagtcag	tttccaggt	agaagcaga	agaagtgtca	5700
ccgagacagc	tgagctgggg	tgccagtggg	gttcttgagg	gcttcaaggga	agcaagggaac	5760
ctctccctct	ttctctctctg	gtctttctct	atgggaccta	gtaataattt	actgcagcca	5820
ccgtgagctg	gaaaaacctag	ccaggtgggg	gaggagagag	tttagttttc	ttgtccctat	5880
tttctctctc	ctggagacat	ccctctctcg	gctttacaaa	gacacagata	caccocggcc	5940
cccacacacac	acacacacac	acacacacac	acacctcctt	aggctggaa	agcagagaat	6000
ggaggggacaa	gggggctgat	tagagccaag	aagaggggag	gaaggagagc	agaggaggaga	6060
gggcagccct	gtttacagtc	acctggctgg	tggggtggca	ggtgctctct	ctgaattaac	6120
cccttgagag	ctggccaggga	ctctggactg	attaccccag	cctgggggtg	catccagggg	6180
ctctaggagg	taaccttttg	ttctccacct	ggatctcttt	tcctccacc	caggtttctg	6240
caggtaatgg	tgccagcagc	ctctcttaca	caaacctcag	agtggcagcc	actctcgcca	6300
actgttaggg	gcactctgccc	cgtctagctg	agtggccagc	cagtgccatt	ccactccact	6360
caggtctctc	agggccacag	ccctgcaccc	ctgtttgggc	tggtgagctg	agacttcagg	6420
tgggctctgc	acagctctct	cagaggcccc	accaatttct	cggacacttc	tcagtgtgtg	6480
gagctcctag	tgggccctctg	aggctcatgc	ctgggaagtg	ttgtgggtgg	ggctcccaag	6540
aggactggcc	cagagagcccc	tgagatagcg	ggatcctga	actggactga	ataaaacgtg	6600
gtctcccaat	ggcgccaaat	ttctgatctt	catctgtgac	ccgtgggcag	caggcgctca	6660
gaatgtgtgt	gagggggctg	ggggaggaga	caggggagcc	aggaggcagt	aaggaggcag	6720
ttgttttgag	aagcaggaga	tgtgaggagg	aggtgacatt	ggggagtagg	ggtggcttga	6780
ggagccacct	ctggctaaac	ctggcagcac	aagagggaag	gggaaacgaa	accaggcng	6840
gctttggagg	gctagctgtga	ctgggctccg	tgactgagct	ctgtgtgcca	gtggctctct	6900
ctctctctcg	ctctggccac	gcctctcttg	ccctggcatt	gggtccccc	aggttgctct	6960
attcttagct	gtccgggtgt	gaagttaatt	cttgggcagt	gataacagcc	cagagttcaac	7020
aggggttgaga	taagcagagct	ctgggtcaga	tcocggcgag	gcacccagcg	cagcccccct	7080
ccctgacccc	ggctncccca	ccagctctgc	gcctctgggg	tggnctccac	aacacctctg	7140
gaatggggaa	tggtttcttg	ttccctgacc	cccttggccc	agggcaegtgt	ctgtctccctc	7200
gacccgattc	ccccaggccc	tgctgctcag	gcttgggaagc	cctgattggg	gctctccacc	7260
agcagccaga	gagctatggt	ccctggcagc	tgtagtcgcg	ctaggccggg	ccaggacacg	7320
tggtggcagg	ggcttagagc	acctgctctg	ggcctctctc	ctcaggccac	cagatccatt	7380
ggttgctctc	gcttagagac	acagcctagc	accctgtctc	ctctccgcct	accacaccca	7440
						7500

```

gcacagaaac tcacaggaat gattgcgctc agggaaaggca gagatgtgcc tggcatcaca 7560
gtttattgtt tataaaccaat gacaataaca gctgttgctc agcacaggcc tagcagagcc 7620
cactgcaggg ggacggcagc gggcaccaga ggccttgctc ggcccaacc aatgggaaca 7680
cccagactca gctgggtccc caaggagagac ttggcacatt ggcatgggtg tgggacaggt 7740
aaagcatgca agaggggagaa gagggcacata aggggcacatc ggctgcgggg tgttgggacc 7800
caaataaata aagcaggatg acagggtccc ctccctcaca ccaggaaatgc ctgacagcgt 7860
ccagcccaaa agcctgcctg tcccaaggctc gtatgtcagc atcaacaggc caggagagctt 7920
ggcaggggcaa gggcagagct ggagatcatg cccagnttcc ctccatggct tgggtaacat 8040
cagcctgggg ggcacaggac agggatggag aaggggctct ctccatggct tgggtaacat 8100
gccaaaggca ggtcataggc cagactcagt ggggggtggg gcctggccta caagcaatgg 8160
agagaacggg ggccatccag agagggtggc agaagagagc ccttgggtca agagaaaact 8186
ttggggaaga caagacacgg gagaag

```

&lt;210&gt; 20

&lt;211&gt; 730

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (26)... (718)

&lt;400&gt; 20

```

cctccccacc catttcaacca ccacc atg aca cgg ggc acc cag tct cct ttc 52
Met Thr Pro Gly Thr Gln Ser Pro Phe
1 5

```

```

ttc ctg ctg ctg ctc ctc aca gtg ett aca gtt gtt aca ggt tct ggt 100
Phe Leu Leu Leu Leu Leu Thr Val Leu Thr Val Thr Gly Ser Gly
10 15 20 25

```

```

cat gca agc tct acc cca ggt gga gaa aag gag act tcg gct acc cag 148
His Ala Ser Ser Thr Pro Gly Gly Glu Lys Glu Thr Ser Ala Thr Gln
30 35 40

```

```

aga agt tca gtg ccc agc tct act gag aag aat gct atc cca gca cgg 196
Arg Ser Ser Val Pro Ser Ser Thr Glu Lys Asn Ala Ile Pro Ala Pro
45 50 55

```

```

act act acc aag agc tgc aga gag aca ttt ctg aaa tgg cca gga tct 244
Thr Thr Thr Lys Ser Cys Arg Glu Thr Phe Leu Lys Trp Pro Gly Ser
60 65 70

```

```

gtg gtg gta caa ttg act ctg gcc ttc cga gaa ggt acc atc aat gtc 292
Val Val Val Gln Leu Thr Ala Phe Arg Glu Gly Thr Ile Asn Val
75 80 85

```

```

cac gac gtg gag aca cag ttc aat cag tat aaa acg gaa gca gcc tct 340
His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala Ala Ser
90 95 100 105

```

```

cga tat aac ctg acg atc tca gac gtc agc gtg agt gat gtg cca ttt 388
Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp Val Pro Phe
110 115 120

```

```

cct ttc tct gcc cag tct ggg gct ggg gtg cca ggc tgg gcc atc gcg 436
Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly Trp Gly Ile Ala
125 130 135

```

ctg ctg gtg ctg gtc tgt gtt ctg gtt gcg ctg gcc att gtc tat ctc 484  
 Leu Leu Val Leu Val Cys Val Leu Val Ala Leu Ala Ile Val Tyr Leu  
 140 145 150  
 att gcc ttg gct gtc tgt cag tgc cgc cga aag aac tac ggg cag ctg 532  
 Ile Ala Leu Ala Val Cys Gln Cys Arg Arg Lys Asn Tyr Gly Gln Leu  
 155 160 165  
 gac atc ttt coa gcc cgg gat acc tac cat cct atg agc gag tac ccc 580  
 Asp Ile Phe Pro Ala Arg Asp Thr Tyr His Pro Met Ser Glu Tyr Pro  
 170 175 180 185  
 acc tac cac acc cat ggg cgc tat gtg ccc cct agc agt acc gat cgt 628  
 Thr Tyr His Thr His Gly Arg Tyr Val Pro Pro Ser Ser Thr Asp Arg  
 190 195 200  
 agc ccc tat gag aag gtt tct gca ggt aat ggt ggc agc agc ctc tct 676  
 Ser Pro Tyr Glu Lys Val Ser Ala Gly Asn Gly Gly Ser Ser Leu Ser  
 205 210 215  
 tac aca aac cca gca gtg gca gcc act tct gcc aac ttg tag gggcagctcg 728  
 Tyr Thr Asn Pro Ala Val Ala Ala Thr Ser Ala Asn Leu  
 220 225 230  
 cc 730

<210> 21  
 <211> 177  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (74)...(177)

<400> 21  
 cagctccacc totcaagcag ccagcgccctg cctgaatctg ttctgcccc tccccaccga 60  
 ttccaccacc acc atg aca ccg ggc acc cag tct cct ttc ttc ctg ctg 109  
 Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu  
 1 5 10  
 ctg ctc ctc aca gtg ctt aca ggt gga gaa aag gag act tcg gct acc 157  
 Leu Leu Leu Thr Val Leu Thr Gly Gly Glu Lys Glu Thr Ser Ala Thr  
 15 20 25  
 cag aga agt toa gtg ccc ag 177  
 Gln Arg Ser Ser Val Pro  
 30

<210> 22  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

gaacagattc aagcagccag

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

cccgggtgca tgggtggtgt

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24

gtgcccggtg tcatggtggt

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25

gaaaggagac tgggtgccog

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26

ctgtaacaac tgtaagcact

20

<210> 27  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27  
acctgtaaca actgtaagca 20

<210> 28  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28  
tcagtagagc tgggcactga 20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29  
gcattcttct cagtagagct 20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30  
agcattcttc tcagtagagc 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31

tggtcactact cacagcattc

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32

ctgctgggtca tactcacagc

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33

gctggagagt acgctgctgg

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34

tgggaccgag gtgacatcct

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

gtgacattgt ggactggagg

20

<210> 36

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36  
gagggtgacat tgtggactgg 20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37  
tgaggccgag gtgacattgt 20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38  
gtggtaggag tatcagagtg 20

<210> 39  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39  
gcaaggggtgg taggagtatc 20

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide



<400> 40  
ggcatcagtc ttggtgctat 20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41  
gagaccccag tagacaactg 20

<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42  
tcttcagag aggaattaaa 20

<210> 43  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43  
aatgtctctc tgcagctctt 20

<210> 44  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44  
tcagaaatgt ctctctgcag 20

<210> 45  
<211> 20

<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45  
tctgcaaaaa catttcagaa 20

<210> 46  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46  
gtttataaat ctgcaaaaac 20

<210> 47  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47  
attggagagc cccagaaaac 20

<210> 48  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48  
taatattgga gaggcccaga 20

<210> 49  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49  
gaacttaata ttggagaggc 20

<210> 50  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50  
agatcctggc ctgaacttaa 20

<210> 51  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51  
cacagatcct ggcctgaact 20

<210> 52  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52  
acgtcgtgga cattgatggt 20

<210> 53  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53  
gttatatcga gaggctgctt 20

<210> 54  
<211> 20  
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

atcgtcaggt tatatcgaga

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

gcacatcact cacgctgacg

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56

ggcagagaaa ggaaatggca

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57

gacagacagc caaggcaatg

20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58

ctgcccgtag ttcttttcggc 20

<210> 59  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59  
tggaagatg tccagctgcc 20

<210> 60  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60  
gctacgatcg gtactgctag 20

<210> 61  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61  
aggtgctgc caccattacc 20

<210> 62  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62  
aagttggcag aagtggtgc 20

<210> 63  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

ctacaagttg gcagaagtgg

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 64

acgtgccctt acaagttggc

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65

gctcagagg cgacgtgcc

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66

ctggccactc agctcagagg

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67

actggctggc cactcagctc

20

<210> 68  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 68  
ggaatggcac tggctggcca  
  
<210> 69  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 69  
ggagtggaaat ggcactggct  
  
<210> 70  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 70  
aggaattaaa agcattcttc  
  
<210> 71  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 71  
cagtagacaa agcattcttc  
  
<210> 72  
<211> 20  
<212> DNA  
<213> Artificial Sequence

20

20

20

20

<220>

<223> Antisense Oligonucleotide

<400> 72

gacagacagc catttcagaa

20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73

catcactcac tgaacttaat

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74

tttgggtttt ocaagtagcc

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75

catagtctcc tcccaggcct

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76

cattttgcct ctgggtgcaa

20



<210> 77  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 77  
cagccccaga catttcagaa  
  
<210> 78  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 78  
ttctctctgc ccataggcct  
  
<210> 79  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 79  
gggtctttat gaaggaaaaa  
  
<210> 80  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 80  
acatcactca catttcagaa  
  
<210> 81  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>

20

20

20

20

<223> Antisense Oligonucleotide

<400> 81

accacgtttt attcagtcca

20

<210> 82

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82

gctgtgtag ctgtaagcac

20

<210> 83

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83

gtgctgggat agcattcttc

20

<210> 84

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84

agagtcaatt gtaccaccac

20

<210> 85

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85

ttttctccac ctgtaagcac

20

<210> 86  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 86  
cctgtaacaa ctgttgccggg  
  
<210> 87  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 87  
tgaccagaac ctgtaacaac  
  
<210> 88  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 88  
tctccttttc tccacctggg  
  
<210> 89  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 89  
ctcagtagag ctgggcactg  
  
<210> 90  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>

20

20

20

20

<223> Antisense Oligonucleotide

<400> 90  
tcatactcac agcattcttc 20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91  
agagcctgag gccgaggtga 20

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92  
gacccacagta gacaactggg 20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93  
aggaattaaa ctggaggttt 20

<210> 94

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94  
gtgctgggat cttccagaga 20

<210> 95

<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 95  
atcctggcct ggtcacaggg  
  
<210> 96  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 96  
cagccccaga ctgggcagag  
  
<210> 97  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 97  
ggccccctttc ttccatagtc  
  
<210> 98  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide  
  
<400> 98  
ccacctggag tggttttcca  
  
<210> 99  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
  
<223> Antisense Oligonucleotide

20

20

20

20

<400> 99  
aaagccgaga gagggagggtc

20

<210> 100  
<211> 336  
<212> DNA  
<213> Homo sapiens

<220>

<400> 100  
accaccacca tgacaccggg caccacgtct cctttctctc tgctgctgct cctcacagtg 60  
cttacacgcta ccacagccccc taaacccgca acagttgtta caggttcttg tcatgcaagc 120  
cttaccacag gtggagaaaa ggagacttcg gctacccaga gaagttcagt gccacgctct 180  
actgagaaga atgctgtgag tatgaccagc agcgtactct ccagccacag ccccggttca 240  
ggctctctca ccaactcagg acaggtatgt actctggccc cggccacgga accagcttca 300  
ggttcagctg ccacctgggg acaggtatgt acctcg 336

<210> 101  
<211> 518  
<212> DNA  
<213> Homo sapiens

<220>

<400> 101  
gagcctgctt gaattctgtt tgcctccctc ccacccattt caccaccacc atgacaccgg 60  
gcaccacagt tctttctctc ctgctgctgc tctctacagt gcttacagct accacagccc 120  
ctaaacccgc aacagttgtt acaggttctg gtcattgcaag ctctacccca ggttgagaaa 180  
aggagacttc ggctacccag agaagttcag tgccacagct tactgagaag aatgctgtga 240  
gtatgaccag cagcgtatct tccagccaca gccccggctc aggtctctcc accactcagg 300  
gacaggatgt cactctggcc ccggccacgg aaccagcttc aggttcagct gccacctggg 360  
gacaggatgt cactctggcc ccagtcacca ggccagccct gggtctccac accccgccag 420  
cccacgatgt cactctggcc ccggacacca agccagcccc gggtctccac gccccccag 480  
cccacgatgt cactctggcc ccggacacca ggccggcc 518

<210> 102  
<211> 3343  
<212> DNA  
<213> Homo sapiens

<220>

<400> 102  
gagctcctgg ccagtggttg agagtggcaa ggaaggacc tagggttcat cggagccag 60  
gtttactccc ttaagtggaa atttctctcc ccactccctt ccttggtttt ctccaaggag 120  
ggaacccacg gctgctggaa agtcggctg gggcggggac tgtgggttcc agggtagaac 180  
tgctgttgga acgggacagg gagcgggttag aagggtgggg ctattccggg aagtgggtgt 240  
ggggggaggg agcccaaaac tagcacctag tccactcatt atccagccct ctattttctc 300  
ggccgctctt gcttcagtg acccggggag ggccggggaag tggagtggga gacctagggg 360  
tgggtctccc gaacttctgt tacaggacct cgacctagct ggctttgttc cccatcccca 420  
gttagttgtt gccttgaggc taaaactaga gccacggggc cccaagttcc agactgccc 480  
tcccctctcc ccggagacca gggagtgttt ggtgaaaggg ggaggccagc tggagaagaa 540  
acgggtagtc aggggttgca gcattagagc ccttgtagcc ctagcccagg aatggttgga 600  
gagagaagag tagagtagg aggggggttt gtcacatgtc acctgctcgg clgtgcttag 660  
ggcggggcgg ggggagtggg gggacgggta taaagcggta ggcgctgtg cccgctccac 720  
ctctcaagca gccagcgct gctgaatct gttctgccc ctccccacc atttcaccac 780  
caccatgaca ccgggcaacc agtctctttt cttctctgtg ctgctcctca cagtgtttac 840

```

aggtgagggg cagcaggttg ggagtgggct gccctgctta ggtggtcttc gtggtcttcc 900
tgtgggtttt gctccctggc agatggcacc agaagttaag gtaagaattg cagacagagg 960
ctgcctcgtc tgtgccagaa ggaggggagag gctaaggaca ggctgagaag agtgcccccc 1020
aacccctaga gtgggtacca ggggcaagca aatgtcctgt agagaagtct aggggggaaga 1080
gagtagggag agggaaggct taagagggga agaaatgcag gggccatgag ccaaggcccta 1140
tgggcagaga gaaggaggct gctgcaggaa ggagggcgcc aaccaggggg ttaactgaggc 1200
tgcccactcc ccagctctcc ttgtattatt tctctgggtg ccaggcttat atttctctct 1260
tgctcttatt ttctcttcat aaagacccaa cctatgact ttaacttctt acagctaacca 1320
cagccccctg gccgcgaaca gttgttacag gttctggtca tgcaagctct caccagagtg 1380
gagaaaagga gactctggct accacagaga gttcagtgcc cagctctaact gagaagaatg 1440
ctgtgagtat gaccagcagc gtactctcca gccacagccc cgggttcaggc tctctccacca 1500
ctcaggggaca ggaatgtcaact ctggcccccgg coacggaaacc agcttcagggt tcagctggcca 1560
cctgggggaca ggaatgtcaacc tcggtcccaag toaccaggccc agccctggggc toaccacccc 1620
gcgcagcccca cgaatgtcaacc tcagccccgg acaacaagcc agccccggggc tccacggccc 1680
ccccagcccca ggggtgtcaacc tcggccccgg agaccaggccc gcccccggggc tccacggccc 1740
ccccagcccca tgggtgtcaacc tcggccccgg acaacaggccc cgccttggggc tccacggccc 1800
ctccagctcca caatgtcaacc tcggcctcag gctctgcaat aggtctcaggt tctactctgg 1860
tgccacaacgg caacctctgc agggctacca caaccccagg cagcaagagc actccattct 1920
caattcccaag ccaccactgc gatactccta ccacctctgc cagccatagc accaagaactg 1980
atgccagtag cactcaccat agcacgggtac ctctctcacc ctctcccaat cacagcaactt 2040
ctccccagtt gtctactggg gtctcttttt ttttctgtc ttttccactt ccaaaagctcc 2100
agtttaattc ctctctggaa gatcccgaca cogaactacta caagagagctg caacagagaca 2160
tttctgaatt ggtgagttat ggccctttctt tocccatgct cccctgaagc agccatcaga 2220
actgtcaaac ccctttccat caagcctgag tcttctccct ctacccccag tttttgcaga 2280
tttataaaca aggggggttt ctggggcctct ccaatattaa gtttcaggtag agttctgggt 2340
gtggaccacg tgtgggtgtt ggagggttggt ttggtgggtc tgagccgtag ggaggggactg 2400
gtgcacttaa gtttgggggg agagtgtctg gccagagctg ggaacccgtg ctgaagtggc 2460
catttccctg tgaccaggcc aggatctgtg ttggtacaaat tgactctggc ctcccgagaa 2520
ggtaccatca atgtccacga cgtggagaca cagtccaact agtataaaac ggaagcagcc 2580
tctcgatata acctgacgat ctcaagagct cagcgtgtag gctacttccc ttctgcagcc 2640
agcaccaatg cggggccccc ctctctccag ttgtctgggt cccgctcttt ccttagtgct 2700
ggcagcggga gggggccctc ctctgggaga ctgcccctgac cactgctttt ccttttagtg 2760
agtgaatgag catttccctt ctctgacacg totggggctg ggggtgccag ctggggcactc 2820
gcgctgctgg tctcgtgtctg ttgtctgggt gogctggcca ttgtctatct cattgctgtg 2880
gtgagtgcag gtgagtgccc tgatcagagc ccccgggtag aaggcactcc atggcctgoc 2940
ataacctctt atctcccaag gctgtctgtc agtgcccgcc aaagaactac gggcagctgg 3000
acactcttcc agcccgggat acctaccatc ctatgagcga gtaccccacc accccaacc 3060
atgggcgcta tgtcccccca cagtagccga tctgagcccc tatgagaagg tgagattggg 3120
ccccacaggg aggggaagca gagggtttgg ctgggcaagg attctgaagg gggtaacttg 3180
aaaaaccaaa gagcttggaa gaggtagaaa ttggcgtgaa gtgagcaggg gagggtctggc 3240
aaggaatgag gtcagagatc agaggagtgt ttgggggacag gctctggagg agactatgga 3300
agaaaggggc ccctacaagg ggagtgcacc actgcagaa ttc 3340

```

&lt;210&gt; 103

&lt;211&gt; 859

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;400&gt; 103

```

ctctccccc ccttoacca ccaccatgac accggggcacc cagtctctct tcttctctgt 60
ctgctctctc acagtctcta cagttgtttac aggttctgggt catgcaagct ctaccccagg 120
tgagaaaaag gagactctcg ctaccocagag aagttcagtg cccagctctca ctgagaagaa 180
tgctttgtct ctttcttttt cctgtctttt cctgtctttt cacatttcaa cctccagtt 240
taattctctt ctggaagatc ccagcacoga ctactaccaa gagctgcaga gagacatttc 300
tgaatgtttt ttgcagattt ataaacaagg gggttttctg ggcctctcca atattaagtt 360
caggccagga tctgtgttg tacaattgac tctggccttc cgagaaggta ccatcaatgt 420
ccacgagctg gagacgcagt tcaatcagta taaacaggaa gcagcctctc gatataacct 480

```

```

gacgatctca gacgtcagcg tgagtgatgt gccatttctt ttctctgcc agtcctggggc 540
tggggtgccca ggtctggggca tgcgctgtgt ggtgctgggtc tgtgtttctgg ttgcgctggc 600
cattgtctat ctcatgtgct tggtctgtctg tcagtgccgc cgaagaagact acgggcagct 660
ggacatcttt ccagcccggtg atacctacca tctatgagc gagtaccoca cctaccacac 720
ccatggggcg tatgtgcccc ctgacagtagc cgatcgtagc ccctatgaga cgggtttctgc 780
aggtaatggt ggacgagcgc tctctttcac aaaccagca gtggcagcca cttctgccaa 840
cttgtagggg cactgcgcc

```

&lt;210&gt; 104

&lt;211&gt; 204

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;400&gt; 104

```

ccgtccacc tctcaagcag ccagcgctg cctgaatctg ttctgcccc tccccccca 60
tttcaccacc accatgacac cgggcaccca gtctctcttc ttctgtctgc tgcctctcac 120
agtgcttaca ggttctgggtc atgcaagctc taccgccagt ggagaaaagg agactctggc 180
taccagaga agttcagtc ccag

```

&lt;210&gt; 105

&lt;211&gt; 556

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 5

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 105

```

acgnggaag agagtaggga gaggaagcg ttaagagggg aagaatgca ggggccatga 60
gccaaaggcct atgggcagag agaaggagcg tgctgcaggg aaggagcgg ccaaccagg 120
ggttactgag gctgccact cccagtcct cctgggtatta ttctctgtg gccagagct 180
tatattttct tctgtctctt attttctctt cataaagacc caacctatg actttaactt 240
cttacagcta ccacagcccc taaccocgca acagttgtta cgggttctgg tcatgcaagc 300
tctaccocag gtggagaaaa ggagacttcg gctaccaga gaagttcagt gccagctct 360
actgagaaga atgctgtgag tatgaccagc agcgtactct ccagccacag ccccggttca 420
ggctcctcca ccactcaggg acaggatgct actctggccc cggccacgga accagcttca 480
ggttcaagct gccacctggg acaggatgct acctctgtcc cagtcaccag gccagccctg 540
ggctccacca ccccg

```

&lt;210&gt; 106

&lt;211&gt; 772

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;400&gt; 106

```

gacctctcaa gcagccagcg cctgcctgaa tctgttctgc cccctcccca cccatttcac 60
caccaccatg acaccgggca cccagtcctc ttctctctgc ctgctgtcc tcacagtgt 120
tacagctacc acagccctca aaccgcgaac agttgttac ggttctggct atgcaagctc 180
taccgccagt ggagaaaagg agacttcggt taccagaga agttcagtc ccagctctac 240
tgagaagaat gcttttaatt cctctctgga agatccagc accgactact accaagact 300
gcagagagac atttctgaaa tgtttttgca gatttataaa caaggggggt ttctgggct 360
ctccaatat aagttcaggc caggatctgt ggtggtacaa ttgactctgg ccttcgaga 420

```



```

aggtaccatc aatgtccaag acgtggagac acagttcact cagtataaac ggaagcagcc 480
tctogatata acctgacgat ctccagacgtc agcgtgagtg atgtgccatt tcctttttctc 540
tgcccatgtc ggggctgggg ttgccaggctc ggggcacgcg ggctgctgtg gctgggtctg 600
tgtcctgggt cgctgggcca ttgtctatct cattgccttg cgctgtcctg tcagtgcgc 660
ggacagaaca cgggcccgtg gacctcttcc cggcccggga tacctacatc ctttgagggg 720
agtccccact acacacccatg gggggattgt gccccttagc gtcccgatcg ac 772

```

<210> 107

<211> 635

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> 472, 482

<223> n = A,T,C or G

<400> 107

```

ggctgggggtg ccagggtggg gcatogcgct gctggtgctg gtctgtgttc tggttgcgct 60
ggccattgtc tatctcattg ctttggtctg ctgtcagtgc cgcggaaga actacgggca 120
gtcggacatc ttccagccc gggataccta ccacccatg agcgagtacc ccacctacca 180
caccatggg cgctatgtgc cccctagcag tacogatcgt agccccctatg agaaggtgag 240
attgggcccc acaggccagg ggaagcagag ggtttggctg ggcaaggatl ctgaaggggg 300
tacttggaaa acccaaaagag cttggaagag gtgagaagt gctggaagtg agcaggggag 360
ggcctggcaa ggatgagggg cagaggtcag aggagttttg ggggacaggc ctgggaggag 420
actatggaa aaaggggccc tcaagaggga gtggcccccac tgccagaatt cntaaaagat 480
onttggcgt ccacattcat cctgggtggc gctgggtgaa ctggtgccac cgtggcagtt 540
ttgttttgtt ttgctttttt gcaccagag gcaaaatggg tggagcacta tgcccagggg 600
agcccttccc gaggagtcca aggggtgago tttttg 635

```